<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03359226</url>
  </required_header>
  <id_info>
    <org_study_id>17-007240</org_study_id>
    <nct_id>NCT03359226</nct_id>
  </id_info>
  <brief_title>Transcutaneous Submandibular Gland Biopsy: Feasibility of Repeat Biopsy as a Progression Marker for Parkinson's Disease</brief_title>
  <official_title>Transcutaneous Submandibular Gland Biopsy: Feasibility of Repeat Biopsy as a Progression Marker for Parkinson&amp;Apos;s Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to perform biopsies of one of the glands that make saliva. The&#xD;
      biopsied tissue will then be analyzed to see if it has changes that occur in Parkinson's&#xD;
      disease. This study will determine whether it is possible to do a second biopsy a few years&#xD;
      after a previous biopsy and determine whether there are changes in the biopsy that would&#xD;
      allow for analysis of disease progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tissue biopsies documenting the presence and density of Lewy type synucleinopathy (LTS) in&#xD;
      living patients with probable Parkinsons disease (PD) would be extremely valuable as a&#xD;
      diagnostic test, as a marker of molecular therapeutic target engagement and as a progression&#xD;
      marker. Based on recent data from our group with both early and advanced PD patients, we&#xD;
      propose to perform a second transcutaneous submandibular gland (SMG) needle core biopsy in 12&#xD;
      patients who have previously been biopsied and had LTS present in their SMG tissue.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Actual">May 31, 2018</completion_date>
  <primary_completion_date type="Actual">May 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of alpha-synuclein in the submandibular gland</measure>
    <time_frame>baseline</time_frame>
    <description>The biopsied submandibular gland tissue will be stained with an antibody for alpha-synuclein. The pathologist will review the slides and determine the number that show positive staining for neuronal elements. He will compare the number of positive slides between the right and left submandibular glands to see if they are similar.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Submandibular gland biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No treatment is being used in this study. Study participants will have bilateral submandibular gland biopsies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Submandibular gland biopsy</intervention_name>
    <description>Needle biopsies of the right and left submandibular glands</description>
    <arm_group_label>Submandibular gland biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. PD patients ages up to age 85.&#xD;
&#xD;
          2. Previous participation in a SMG biopsy study at Mayo Clinic Arizona with a positive&#xD;
             biopsy being reported&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Evidence for dementia that would preclude the patient from signing informed consent&#xD;
&#xD;
          2. History of bleeding diathesis or hematologic disorders&#xD;
&#xD;
          3. Medically unable to undergo a core needle biopsy of the submandibular gland&#xD;
&#xD;
          4. Prior treatment of the submandibular gland with botulinum toxin injections.&#xD;
&#xD;
          5. History of past or current acute infection or abscess of the submandibular gland.&#xD;
&#xD;
          6. History of past or current neoplastic process within the submandibular gland.&#xD;
&#xD;
          7. History of peripheral neuropathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles H Adler</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2017</study_first_posted>
  <last_update_submitted>November 5, 2018</last_update_submitted>
  <last_update_submitted_qc>November 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Charles Adler</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

